Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.68 |
| ▸ | FNTB | P49356 | 6/20 | 0.68 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.66 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.59 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12511782 | 0.98 | FNTA (0.66) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL13146186 | 0.98 | FNTA (0.66) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL1723041 | 0.90 | FNTA (0.71) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL1722741 | 0.90 | FNTA (0.71) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL13142545 | 0.88 | FNTA (0.68) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL13142546 | 0.88 | FNTA (0.62) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL3951718 | 0.86 | FNTA (0.65) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL3951716 | 0.86 | FNTA (0.65) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL13146316 | 0.86 | FNTA (0.65) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL8940673 | 0.85 | FNTA (0.67) | FNTAFNTBPGGT1BTRPV1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362283-A1 | NISIN-BASED COMPOUNDS AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362283-A1 | NISIN-BASED COMPOUNDS AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | NISCH, VIP, NGLY1 | FNTA 418/4885FNTB 166/4885PGGT1B 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.